were numerous (50 counts / 10 high power field) (Figure 3 ). In the background of the tumor cells, interspersed small lymphocytes were evident, and some of them were seen around the blood vessels. Lymphoid follicles were recognizable in some areas of the tumor. Regional lymph node involvement of the tumor with sparing of some lymph follicles was also noted.
The results of immunohistochemistry are summarized in Table 1 A final diagnosis of FDCS was made on these findings.
[Discussion]
FDCS is a neoplasm consisting of spindle to ovoid cells, which closely mimics various types of tumors and tumor-like lesions. Typically, they are nodal in origin, but extranodal involvement including the small intestine has been reported 1 . In case of intestinal FDCS, the major differential diagnosis includes gastrointestinal stromal tumor (GIST) and primary intestinal lymphomas. In this case, GIST was easily excluded by a lack of expression of CD34 and c-kit in the tumor cells. Expression of T-cell markers, including CD4 and CD45RO, however, might have lead to a diagnosis of T-cell lymphoma of intestinal origin. Enteropathy-type T-cell lymphomas among Japanese are type 2 in most cases, and are phenotypically characterized by positivity of CD8 and CD56 2 . Peripheral T-cell lymphoma, not otherwise specified, often demonstrates CD4 with frequent loss of CD5 or CD7. However, complete loss of pan-T-cell markers is unusual for T-cell lymphoma. In our case, the possibility of aberrant expression of T-cell antigens in a non-lymphoid tumor was considered. Infiltration of small lymphocytes, especially around the blood vessels, suggested the possibility of FDCS 3) .
For investigation of undifferentiated neoplasm, including FDCS in the differential diagnosis is important since follicular dendritic cell markers are usually not included in the first panel of antibodies. To diagnose FDCS, at least one FDC marker (CD21, CD35, CD23, KiM4p and CNA.42) should be positive and CD1a should be negative 3) . For lymphoid markers, CD20 and CD45(LCA) have been reported to be occasionally positive, while CD3, a pan-T-cell marker, is consistently negative 3 . Our case suggests that even some T-cell associated antigens can be demonstrated in FDCS.
Although CD4 is a co-receptor acting in the activation of T-helper cells by the MHC class II antigen restricted pathway, CD4 expression is not restricted to T lymphocytes. Langerhans' cells, plasmacytoid dendritic cells/monocytes and true histiocytic sarcomas are known to be positive for CD4 4, 5 . Likewise, CD45RO, recognized by antibody UCHL-1 and once widely used as a T-cell marker on paraffin sections 6 , can be expressed in histiocytic tumors 7 . Actually, both CD4 and CD45RO lack lineage specificity and are commonly expressed by histiocytic sarcoma 8 .
Additionally, our case expressed CD68, one of the most available histiocytic markers. For diagnosis of histiocytic sarcoma, however, dendritic cell markers should be negative and other histiocyte-specific markers such as lysozyme or CD163 are usually expressed. In this case, the tumor cells were negative for CD68, and CD163 was not available. Differential diagnosis from the CD4+ blastic plasmacytoid dendritic cell neoplasm would be straight forward, because of non-hematodermic distribution, more sarcomatous morphology, and negativity for immunoreactive CD56 in this case.
Chan et al. reported that mitotic rate of FDCS is usually between 0 and 10/10HPF and Ki-67 labeling index are between 1 and 25% (mean 13%) 3 . In contrast, our case showed high proliferative index (mitotic rate of 50/10 high power fields and Ki-67 labeling index of 90%). As poor prognostic factors of FDCS, significant cytologic atypia, extensive 6 coagulative necrosis, a high proliferative index, large tumor size (> 6cm) or intraabdominl location are documented 3 , and our case meets the all factors. Moreover, to the best of our knowledge, there have been 7 reported cases of primary gastrointestinal FDCS [9] [10] [11] [12] [13] [14] [15] , and 6 among the 7 showed recurrence and/or metastasis. In our case, regional lymph node metastasis is found. Considering those findings, we think that our case is a high-grade malignancy, and that careful follow-up is needed.
In summary, we present a case of FDCS of small intestine origin. Expression of CD45RO was a feature that has not been previously reported. 
